DFDA

Pegylated Interferon-alpha

Treatment for Acute Hepatitis E

Typical Dosage: 180 mcg subcutaneously once weekly

Effectiveness
60%
Safety Score
30%
Clinical Trials
30
Participants
1.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
180 mcg subcutaneously once weekly
Time to Effect
2-4 weeks
Treatment Duration
3-6 months
Evidence Quality
LOW
Confidence Score
60%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$35,000
Monitoring:$1,400
Side Effect Mgmt:$1,000
Total Annual:$37,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$180,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$62,333.33
Cost per Remission
$68,000
Comparison vs Ribavirin
Cost Difference
+$30,000/year
More expensive
QALY Difference
-0.40 QALYs
Worse outcomes
Dominance
No dominance
Pegylated Interferon-alpha Outcomes

for Acute Hepatitis E

Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+60%
Remission Rate
+55%
Common Side Effects
Flu-like symptoms
+60%
Neuropsychiatric effects (e.g., depression)
+30%
Hematologic abnormalities (leukopenia, thrombocytopenia)
+25%
Thyroid dysfunction
+8%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov